Navigation Links
Malaria Vaccine Developer Sanaria Inc. Receives the Technology Council of Maryland's Emerging Company of the Year Award
Date:5/19/2008

ROCKVILLE, Md., May 19 /PRNewswire-USNewswire/ -- On Thursday May 15, 2008 Sanaria Inc. was named Emerging Company of the Year at the annual Technology Council of Maryland's Tech Awards Celebration honoring the state's technology leaders and organizations.

http://techcouncilmd.com/News/tcmnews_080516.html

"All the members of the Sanaria team go to work every day with only one goal in mind, to develop a vaccine that will prevent millions of deaths from malaria," said Sanaria founder and CEO, Stephen L. Hoffman. "I am honored to accept this award on their behalf, and on behalf of our partners who have invested so much in us."

The PATH Malaria Vaccine Initiative, which is partnering with Sanaria Inc. to accelerate development of the company's novel malaria vaccine candidate, welcomed the news. "We at MVI are pleased at the recognition of our partner's efforts to establish a core platform technology for producing attenuated sporozoite malaria vaccines," said Director Dr. Christian Loucq.

The annual dinner and awards celebration was attended by Maryland Governor Martin O'Malley, additional state and local government representatives, and over 900 members of the Maryland technology and biotech industries.

About Sanaria Inc., The company's primary mission is to develop and commercialize a malaria sporozoite vaccine against Plasmodium falciparum, the parasite responsible for more than 95 percent of malaria-associated severe illness and death worldwide, and the malaria parasite for which there is the most significant drug resistance. Sanaria's corporate headquarters, administrative, research, development, and manufacturing operations are located in Rockville, Maryland. The company's Web site is http://www.sanaria.com.

Except for historical information, this news release contains certain forward-looking statements that involve known and unknown risks and uncertainties, which may cause actual results to differ materially from any future results, performance or achievements expressed or implied by the statements made. These forward-looking statements relate to the use of funds to date to complete manufacturing the vaccine, and conduct initial clinical studies. Such risks and uncertainties include, but are not limited to, the Company's ability to raise funds on reasonable terms, the regulatory approval process, competitive products, and maintenance of its patent portfolio, among others.

Media contact: Adam Richman, Sanaria Inc., 9800 Medical Center Drive, Suite A209, Rockville, MD 20850 USA

Ph: +1-301-770-3222

Fax: +1-301-770-5554

Email: arichman@sanaria.com


'/>"/>
SOURCE Sanaria Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. SAIC Awarded Malaria Vaccine Production Support Contract Extension by the National Institute of Allergy and Infectious Diseases
2. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
3. UPDATE: Infant Primates Given Vaccines on U.S. Childrens Immunization Schedule Develop Behavioral Symptoms of Autism
4. Infant Vaccines Produce Autism Symptoms in New Primate Study by University of Pittsburgh Scientists
5. Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial
6. Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation
7. Annual Conference on Vaccine Research to Highlight Not Only Health Benefits But Also Economic Gains
8. Quantum Immunologics, Inc. and the South Alabama Medical Science Foundation Announce an Early Clinical Evaluation of a Novel Immuno-therapeutic Vaccine for Treating Advanced Human Breast Carcinomas
9. Novavax Reports Positive Results from Preclinical Studies of its VLP-based Trivalent Seasonal Influenza Vaccine Candidate
10. Aeras, Crucell and South African Tuberculosis Vaccine Initiative Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa
11. Vical Receives NIH Grant for an Immunotherapeutic Herpes DNA Vaccine; Herpes Experts at University of Washington and University of Texas to Conduct Preclinical Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2017)... , May 15, 2017 Enterin Inc., a ... and developing novel compounds to treat Parkinson,s disease (PD), ... study is a Phase 1/2a randomized, controlled, multicenter study involving ... It will enroll 50 patients over a 9-to-12-month period. The ... in 10 patients with PD. Participating sites include ...
(Date:5/11/2017)... , May 11, 2017  Thornhill Research ... has been awarded an $8,049,024 USD five-year, firm-fixed-priced, ... through the Canadian Commercial Corporation (CCC) ( ... Anesthesia Systems to administer general anesthesia to patients ... "The US Marine Corps have been ...
(Date:5/10/2017)... , May 10, 2017 Global Health Intelligence ... Latin America , published its 2017 ranking of ... is based on extensive data analysis from GHI,s hospitals ... hospitals database for the region. The GHI database covers 86% ... offering more than 130 data points for each institution in ...
Breaking Medicine Technology:
(Date:5/24/2017)... ... May 24, 2017 , ... Last month, representatives ... hospital employees, and town officials to celebrate the grand opening of the 87,000 ... Rendina as part of its ongoing relationship with RWJBarnabas Health, New Jersey’s largest ...
(Date:5/24/2017)... ... May 24, 2017 , ... Dr. Alan I. Benvenisty, MD is dual board ... He is known for his distinguished expertise and experience in the diagnosis and treatment ... training in treating renovascular disease and aortic aneurysm . He is known for ...
(Date:5/24/2017)... ... May 24, 2017 , ... ... and interpretation, has received U.S. Food and Drug Administration (FDA) 510(k) clearance ... scalable and secure cloud platform for medical image management. At the core is ...
(Date:5/24/2017)... ... 2017 , ... Dr. Manju R. Kejriwal, a leading Ohio dentist, is now ... a referral. Dr. Kejriwal understands the emotional and financial toll traditional orthodontics can take ... Patients no longer need to feel the esthetic effects of wires and brackets when ...
(Date:5/24/2017)... ... May 24, 2017 , ... STATEMENT OPPOSING ... vehemently opposed to Donald Trump’s budget, “A New Foundation for American Greatness—President's Budget ... demonizes the poor, marginalizes underserved populations, undermines productivity, and destroys the social safety ...
Breaking Medicine News(10 mins):